Suppr超能文献

减少甲状旁腺功能亢进治疗中的差异。

Reducing disparities in the treatment of hyperparathyroidism.

作者信息

Gillis Andrea, Wang Rongzhi, Zmijewski Polina V, McLeod M Chandler, Ramonell Kimberly, Fazendin Jessica, Chen Herbert, Lindeman Brenessa

机构信息

Department of General Surgery, University of Alabama at Birmingham, Birmingham, AL, USA.

Department of Surgery, University of Pittsburgh, PA, USA.

出版信息

Heliyon. 2024 May 31;10(11):e32244. doi: 10.1016/j.heliyon.2024.e32244. eCollection 2024 Jun 15.

Abstract

BACKGROUND

Hyperparathyroidism is common with African American patients historically experiencing disparate outcomes. With a comprehensive outreach program and systematic treatment plans, we sought to evaluate our institution's ability to reduce disparities in hyperparathyroidism.

METHODS

We performed a retrospective review of prospectively collected data at a single medical center for all patients undergoing parathyroidectomy by endocrine surgeons from 2015 to 2021 for primary (PHPT) and tertiary (THPT) hyperparathyroidism. Patient demographics, pre-and post-operative clinical and biochemical data were collected and analyzed by race.

RESULTS

Of the 757 patients included, 675 patients had PHPT with 135 (20 %) African-American (AA) and 528(78 %) female. Of 82 patients with THPT, 44 (53 %) were AA and 34 (32 %) were female. AA patients were younger than Caucasian (CA) patients with a mean age (±SD) of 56 ± 15 vs 60 ± 14 years in PHPT (p < 0.01) and 50 ± 10 vs 55 ± 10 years in THPT (p = 0.02).Median (IQR) preoperative PTH was higher in AA with PHPT 134 (97-190) vs 102 (75-144) pg/mL (p < 0.01) and in AA with THPT 285 (189-544) vs 218 (145-293) (p = 0.01) pg/mL. AA PHPT patients had significantly higher preoperative mean (±SD) calcium levels 10.9 ± 0.8 vs 10.6 ± 0.8 mg/dL(p < 0.001). Biochemical cure rates at 6 months and complication rates were not different between races.

CONCLUSIONS

AA patients with PHPT and THPT disease experienced similar cure rates to their CA counterparts despite having a more severe biochemical disease. Health care disparities may be ameliorated with treatment by high volume surgeons embedded in a comprehensive health care system.

摘要

背景

甲状旁腺功能亢进症很常见,非裔美国患者历来预后存在差异。通过全面的外展计划和系统的治疗方案,我们试图评估我们机构减少甲状旁腺功能亢进症差异的能力。

方法

我们对一家单一医疗中心前瞻性收集的数据进行了回顾性分析,这些数据来自2015年至2021年由内分泌外科医生为原发性(PHPT)和三发性(THPT)甲状旁腺功能亢进症患者进行甲状旁腺切除术的所有患者。收集患者人口统计学资料、术前和术后临床及生化数据,并按种族进行分析。

结果

在纳入的757例患者中,675例患有PHPT,其中135例(20%)为非裔美国人(AA),528例(78%)为女性。在82例THPT患者中,44例(53%)为AA,34例(32%)为女性。AA患者比白种人(CA)患者年轻,PHPT患者的平均年龄(±标准差)为56±15岁,而CA患者为60±14岁(p<0.01);THPT患者中,AA患者平均年龄为50±10岁,CA患者为55±10岁(p=0.02)。PHPT的AA患者术前甲状旁腺激素(PTH)中位数(四分位间距)较高,为134(97-190)pg/mL,而CA患者为102(75-144)pg/mL(p<0.01);THPT的AA患者术前PTH为285(189-544)pg/mL,CA患者为218(145-293)pg/mL(p=0.01)。PHPT的AA患者术前平均(±标准差)血钙水平显著更高,为10.9±0.8mg/dL,而CA患者为10.6±0.8mg/dL(p<0.001)。6个月时的生化治愈率和并发症发生率在不同种族之间没有差异。

结论

患有PHPT和THPT疾病的AA患者尽管生化疾病更严重,但其治愈率与CA患者相似。在综合医疗保健系统中,由经验丰富的外科医生进行治疗可能会改善医疗保健差异。

相似文献

1
Reducing disparities in the treatment of hyperparathyroidism.
Heliyon. 2024 May 31;10(11):e32244. doi: 10.1016/j.heliyon.2024.e32244. eCollection 2024 Jun 15.
2
Racial Disparities in Primary Hyperparathyroidism.
World J Surg. 2021 Jan;45(1):180-187. doi: 10.1007/s00268-020-05791-w. Epub 2020 Sep 25.
3
BIOCHEMICAL DYNAMICS OF UNTREATED PRIMARY HYPERPARATHYROIDISM: AN OBSERVATIONAL STUDY.
Endocr Pract. 2019 May;25(5):470-476. doi: 10.4158/EP-2018-0489. Epub 2019 Jan 18.
4
Intraoperative Parathyroid Hormone Monitoring in Parathyroidectomy for Tertiary Hyperparathyroidism.
J Surg Res. 2019 Dec;244:77-83. doi: 10.1016/j.jss.2019.06.020. Epub 2019 Jul 4.
5
Parathyroidectomy for Normocalcemic Tertiary Hyperparathyroidism: A 19-Year Experience.
J Surg Res. 2022 Aug;276:362-368. doi: 10.1016/j.jss.2022.02.011. Epub 2022 Apr 13.
7
Tertiary hyperparathyroidism: histologic patterns of disease and results of parathyroidectomy.
Arch Surg. 2004 Sep;139(9):974-7. doi: 10.1001/archsurg.139.9.974.
8
A comparison of outcomes for younger and older adult patients undergoing surgery for primary hyperparathyroidism.
Ann Surg Oncol. 2012 Jun;19(6):1897-901. doi: 10.1245/s10434-011-2185-2. Epub 2011 Dec 30.
9
Analysis of Preoperative Predictors of Single and Multigland Primary Hyperparathyroidism.
J Surg Res. 2023 Aug;288:148-156. doi: 10.1016/j.jss.2023.02.011. Epub 2023 Mar 24.
10
Surgical treatment of patients with mildly elevated parathormone and calcium levels.
World J Surg. 2014 Jun;38(6):1289-95. doi: 10.1007/s00268-014-2487-1.

本文引用的文献

1
Getting Your Foot in the Door: Access to Surgical Care for Thyroid Disease.
J Surg Res. 2023 Mar;283:344-350. doi: 10.1016/j.jss.2022.11.005. Epub 2022 Nov 22.
2
Black patients are more likely to undergo parathyroidectomy for secondary hyperparathyroidism.
Surgery. 2023 Jan;173(1):111-116. doi: 10.1016/j.surg.2022.05.040. Epub 2022 Oct 1.
3
Comparative utility of preoperative imaging in normocalcemic versus hypercalcemic primary hyperparathyroidism.
Am J Surg. 2023 Feb;225(2):293-297. doi: 10.1016/j.amjsurg.2022.09.042. Epub 2022 Sep 24.
4
Disparities in unplanned surgery amongst medicare beneficiaries.
Am J Surg. 2023 Apr;225(4):602-607. doi: 10.1016/j.amjsurg.2022.08.018. Epub 2022 Aug 28.
6
Is preoperative parathyroid localization necessary for tertiary hyperparathyroidism?
Am J Surg. 2022 Sep;224(3):918-922. doi: 10.1016/j.amjsurg.2022.05.002. Epub 2022 May 6.
7
Vitamin D deficiency is associated with single gland parathyroid disease.
Am J Surg. 2022 Sep;224(3):914-917. doi: 10.1016/j.amjsurg.2022.04.005. Epub 2022 Apr 15.
9
Use and disparities in parathyroidectomy for symptomatic primary hyperparathyroidism in the Medicare population.
Surgery. 2021 Nov;170(5):1376-1382. doi: 10.1016/j.surg.2021.05.026. Epub 2021 Jun 12.
10
My surgical practice: Radioguided parathyroid surgery, how and why we use it.
Am J Surg. 2022 Jan;223(1):203-205. doi: 10.1016/j.amjsurg.2021.06.001. Epub 2021 Jun 9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验